EICHOR
● Active Not Recruiting
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Condition: Non-small Cell Lung Cancer · Sponsor: Merck Sharp & Dohme LLC
About this study
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (227)
| Banner MD Anderson Cancer Center ( Site 0028) | Gilbert, Arizona, United States | — |
| Western Regional Medical Center, Inc. ( Site 0050) | Goodyear, Arizona, United States | — |
| University of Arizona Cancer Center - Dignity Health ( Site 0062) | Phoenix, Arizona, United States | — |
| University of Arizona Cancer Center ( Site 0012) | Tucson, Arizona, United States | — |
| Pacific Cancer Medical Center, Inc. ( Site 0004) | Anaheim, California, United States | — |
| Providence Saint Joseph Medical Center ( Site 0061) | Burbank, California, United States | — |
| Pacific Cancer Care ( Site 0035) | Monterey, California, United States | — |
| John Wayne Cancer Institute ( Site 0049) | Santa Monica, California, United States | — |
| St Joseph Heritage Healthcare ( Site 0040) | Santa Rosa, California, United States | — |
| Stanford University, Stanford Cancer Center ( Site 0046) | Stanford, California, United States | — |
| Hartford Hospital ( Site 0069) | Hartford, Connecticut, United States | — |
| Helen F. Graham Cancer Center & Research Institute ( Site 0015) | Newark, Delaware, United States | — |
+ 215 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03425643